Illumina (ILMN) : Zevin Asset Management added new position in Illumina during the most recent quarter end. The investment management firm now holds 18,430 shares of Illumina which is valued at $3,096,609 , the company said in a statement filed on Aug 8, 2016 with the SEC.Illumina makes up approximately 0.83% of Zevin Asset Management’s portfolio.
Other Hedge Funds, Including , Ropes Wealth Advisors boosted its stake in ILMN in the latest quarter, The investment management firm added 363 additional shares and now holds a total of 863 shares of Illumina which is valued at $145,001. Illumina makes up approx 0.05% of Ropes Wealth Advisors’s portfolio. Herndon Capital Management added ILMN to its portfolio by purchasing 14 company shares during the most recent quarter which is valued at $2,329.Quadrant Capital Group reduced its stake in ILMN by selling 32 shares or 5.97% in the most recent quarter. The Hedge Fund company now holds 504 shares of ILMN which is valued at $83,840. Illumina makes up approx 0.05% of Quadrant Capital Group’s portfolio.Nordea Investment Management Ab reduced its stake in ILMN by selling 90 shares or 1.59% in the most recent quarter. The Hedge Fund company now holds 5,587 shares of ILMN which is valued at $852,520.
Illumina opened for trading at $167.4 and hit $174.48 on the upside on Monday, eventually ending the session at $173.36, with a gain of 3.81% or 6.37 points. The heightened volatility saw the trading volume jump to 14,12,693 shares. Company has a market cap of $25,415 M.
On the company’s financial health, Illumina reported $0.71 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on May 3, 2016. Analyst had a consensus of $0.74. The company had revenue of $571.80 million for the quarter, compared to analysts expectations of $580.44 million. The company’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.91 EPS.
Many Wall Street Analysts have commented on Illumina. Company shares were Reiterated by Mizuho on Jul 27, 2016 to “Neutral”, Firm has raised the Price Target to $ 148 from a previous price target of $138 .Shares were Downgraded by Morgan Stanley on Jul 5, 2016 to ” Underweight” and Lowered the Price Target to $ 110 from a previous price target of $130 .Illumina was Initiated by CL King to “Buy” on Jun 22, 2016.
Illumina Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms reagent kits and scanning equipment. Its customers include genomic research centers academic institutions government laboratories hospitals and reference laboratories pharmaceutical biotechnology agrigenomics commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research including de novo sequencing genetic variation analysis epigenetics and targeted screening among others. It also provides products and services for other life sciences applied markets such as agrigenomics. It also offers Clarity Run Manager Clarity LIMS Silver and Clarity LIMS Gold.